A long-acting platelet-boosting fusion protein drug and its uses

By introducing specific amino acid mutations and eukaryotic expression systems into the Fc fragment, the limitations of the production process and safety issues of TPO receptor agonists have been resolved, enabling the efficient and safe production of long-acting thrombopoietin receptor agonists, thus improving production quality and the flexibility of clinical application.

CN123106925APending Publication Date: 2026-11-17BIO-AOJIYUAN (SHANDONG) BIOPHARMACEUTICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611475402.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing TPO receptor agonists suffer from limitations in manufacturing processes, passive safety design, and short half-lives, making it impossible to achieve a combination of proactive safety design and long-lasting effects while maintaining efficient production.

Method used

The long-acting thrombopoietin receptor agonist fusion protein, which has undergone multiple engineering modifications, has been optimized in terms of production process and reduced immunogenicity risk by introducing specific amino acid mutations, such as L234S, L235T, G236R, N297G, M252Y, S254T and T256E, into the Fc fragment and combining it with a eukaryotic expression system. This has extended the half-life.

Benefits of technology

It has enabled high-quality, high-volume production, reduced immune-related adverse reactions, provided long-lasting drug effects, and enhanced the flexibility and safety of clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106925A_ABST
    Figure CN123106925A_ABST
Patent Text Reader

Abstract

This invention provides a long-acting platelet-boosting drug fusion protein. The fusion protein comprises an Fc variant fragment and a thrombopoietin-binding peptide fragment, wherein the Fc variant fragment incorporates an Fc effector-inactivating mutation selected from positions 234, 235, and 236, and / or positions 234 and 235 of the EU index, and / or a deglycosylation mutation at position 297, and / or a half-life-extending mutation at positions 252, 254, and 256. By actively introducing Fc effector-inactivating mutations, deglycosylation mutations, and half-life-extending mutations, the molecule designed in this invention reduces the antibody Fc fragment-mediated effector function and cytotoxicity at the molecular design level, while simultaneously reducing the immunogenicity risk of the molecule as a drug and extending its half-life in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of proteins, specifically to a long-acting platelet-boosting drug fusion protein and its uses. Background Technology

[0002] Thrombocytopenia is a common bleeding disorder characterized by a significant decrease in the platelet count in peripheral blood. It is frequently seen in various clinical situations, including bone marrow suppression following chemotherapy for cancer, immune thrombocytopenic purpura (ITP), chronic liver disease, and aplastic anemia. A severe decrease in platelet count can significantly increase the risk of spontaneous bleeding, seriously threatening the patient's life and health.

[0003] Currently, thrombopoietin (TPO) receptor agonists have become first-line drugs for the treatment of thrombocytopenia. These drugs specifically activate TPO receptors on the surface of megakaryocytes by mimicking the biological function of endogenous TPO, thereby promoting megakaryocyte proliferation, differentiation, and platelet production.

[0004] Roprostine, a second-generation TPO receptor agonist fusion protein, is composed of a TPO mimic peptide linked to a human IgG1 Fc fragment via peptide bonds and produced using an E. coli prokaryotic expression system. Despite achieving some clinical efficacy, this technology suffers from three fundamental drawbacks: its manufacturing process has inherent limitations; the prokaryotic system cannot achieve proper glycosylation and folding of the Fc fragment, resulting in products often existing as inclusion bodies; the process is complex and batch-to-batch consistency is poor; its safety profile is a "passive defect" rather than an active design feature; and its pharmacokinetic properties are insufficient, with a half-life of only 3-5 days, requiring weekly dosing and leading to poor patient compliance.

[0005] In existing technologies, improvements addressing the aforementioned shortcomings often employ a single-dimensional strategy: either optimizing only the expression system, modifying only the Fc function, or simply extending the half-life. These fragmented improvements fail to create a synergistic effect, failing to achieve an organic combination of proactive safety design and longevity while maintaining efficient production. Therefore, there is an urgent need in the field for a systematic and comprehensive solution capable of simultaneously addressing these three interrelated technical challenges: manufacturability, safety, and longevity. Summary of the Invention

[0006] This invention aims to overcome the technical defects of existing TPO receptor agonists, such as limitations in production processes, passive safety design, and short half-life, and to provide a long-acting thrombopoietin receptor agonist fusion protein that has undergone multiple engineering modifications.

[0007] In a first aspect, the present invention provides a long-acting platelet-boosting drug fusion protein, the fusion protein comprising: an Fc variant fragment of human immunoglobulin G (IgG) and a thrombopoietin receptor-binding peptide fragment, wherein: A1) The Fc fragment contains a mutated sequence of amino acids from position 221 (D221) to position 449 (K449) of the EU index corresponding to wild-type IgG1; A2) The Fc fragment contains an amino acid fragment from the CH2-CH3 region corresponding to wild-type IgG2 or mutant IgG2; The A3)Fc fragment contains an amino acid fragment from the CH2-CH3 region corresponding to wild-type IgG4 or mutant IgG4.

[0008] Optionally, the Fc variant fragment includes the introduction of one or more amino acid substitutions selected from the group consisting of the amino acid sequence shown in SEQ ID NO: 14: B1) Replacement at positions 234, 235, and 236 of the EU index. B2) Replacement at positions 234 and 235 of the EU index. B3) Replacement located at position 297 of the EU index. B4) Replacement at positions 252, 254, and 256 of the EU index.

[0009] Optionally, the IgG1 Fc mutant fragment includes substitutions at positions 234, 235, and 236 of the EU index, and / or at position 297 of the EU index, and / or at positions 252, 254, and 256 of the EU index.

[0010] Optionally, the thrombopoietin (TPO) mimic peptide fragment contains an amino acid sequence that has at least 90% sequence identity with SEQ ID NO: 1 and retains TPO receptor agonistic activity.

[0011] Furthermore, the amino acid is substituted as follows: C1) The substitutions located at positions 234, 235, and 236 of the EU index are L234S, L235T, and G236R, respectively; C2) The substitutions located at positions 234 and 235 of the EU index are L234A and L235A, respectively; C3) The substitution located at the 297th position of the EU index is N297G or N297Q; C4) The replacements at positions 252, 254, and 256 of the EU index are M252Y, S254T, and T256E, respectively.

[0012] Optionally, the Fc variant fragment includes an N297G substitution introduced at position 297 of the EU index in the amino acid sequence shown in SEQ ID NO: 14.

[0013] Optionally, the Fc variant fragment includes the introduction of L234A and L235A substitutions at positions 234 and 235 of the EU index in the amino acid sequence shown in SEQ ID NO: 14; N297G substitution at position 297 of the EU index; and M252Y, S254T, and T256E substitutions at positions 252, 254, and 256 of the EU index.

[0014] Further, the Fc variant fragment and the thrombopoietin receptor-binding peptide fragment are directly linked or linked via a flexible molecule. In one specific embodiment of the invention, the Fc variant fragment and the thrombopoietin receptor-binding peptide fragment are linked via a flexible molecule. Optionally, the flexible molecule is at least one of (GGGGS)n and (G)n, where n is an integer from 1 to 5.

[0015] In one specific embodiment of the present invention, the structure of the fusion protein is: human IgG1 Fc variant fragment-(G)5 linker peptide-double tandem TPO mimic peptide fragment.

[0016] Furthermore, the amino acid sequence of the fusion protein includes at least one of the following: D1) The amino acid sequence as shown in SEQ ID NO: 2 or 7; D2) is a protein obtained by substituting and / or deleting and / or adding amino acid residues from the amino acid sequence of the mutant described in D1), which has more than 90% identity with the fusion protein described in D1) and has the same function. D3) A fusion protein with the same function is obtained by linking a tag protein to the N-terminus and / or C-terminus of the mutant described in D1) and / or D2).

[0017] The fusion protein comprises the amino acid sequences of the following six specific embodiments: A fusion protein containing the N297G mutation, the amino acid sequence of which is shown in SEQ ID NO: 2; A fusion protein containing L234S, L235T and G236R mutations, the amino acid sequence of which is shown in SEQ ID NO: 3; A fusion protein containing both N297G mutation and L234S, L235T and G236R mutations, the amino acid sequence of which is shown in SEQ ID NO: 4; The fusion protein containing N297G mutation, L234S, L235T, G236R mutation, and M252Y, S254T and T256E mutation has the amino acid sequence shown in SEQ ID NO: 5. A fusion protein containing N297G mutation, M252Y, S254T and T256E mutation, the amino acid sequence of which is shown in SEQ ID NO: 6; The fusion protein contains N297G mutation, M252Y, S254T and T256E mutation, as well as L234A and L235A mutation, and its amino acid sequence is shown in SEQ ID NO: 7.

[0018] Furthermore, the Fc variant fragment also includes one or more amino acid substitutions capable of extending the in vivo half-life of the fusion protein. These half-life-extending amino acid substitutions include substitutions corresponding to EU index positions 252, 254, and 256 of the IgG heavy chain. Preferably, the substitutions are M252Y, S254T, and T256E, respectively.

[0019] Furthermore, the affinity of the fusion protein for the corresponding Fc receptors (FcYRI, FcYRIIa, FcYRIII, and C1q) is reduced compared to wild-type Fc as follows: Compared with wild-type Fc fusion proteins, the affinity is reduced by 5 times or more; Compared with wild-type Fc fusion proteins, the affinity is reduced by 10 times or more; Compared with wild-type Fc fusion proteins, the affinity is reduced by 25 times or more; Compared with wild-type Fc fusion proteins, the affinity is reduced by 50 times or more; Compared with wild-type Fc fusion proteins, the affinity is reduced by 100 times or more; Compared with wild-type Fc fusion proteins, the affinity is reduced by 1000 times or more; Compared to wild-type Fc fusion proteins, the affinity is almost nonexistent.

[0020] Furthermore, the affinity of the fusion protein for the corresponding FcRn receptor wild-type Fc is increased, to the extent that: Compared with wild-type Fc fusion proteins, the affinity is increased by 5 times or more; Compared with wild-type Fc fusion proteins, the affinity is increased by 10 times or more; Compared with wild-type Fc fusion proteins, the affinity is increased by 100 times or more; Compared with wild-type Fc fusion proteins, the affinity is increased by 1000 times or more.

[0021] Furthermore, the fusion protein can promote the proliferation of platelets and platelet-like cells, with the following relative proliferation index: The relative growth rate is 2 times or higher; The relative growth index is 4 times or higher; The relative growth rate is 8 times or higher; The relative proliferation index is 16 times or higher.

[0022] Furthermore, the concentration of the fusion protein agonist used to promote the proliferation of platelets and platelet-like cells by the fusion protein is as follows: The concentration of the fusion protein agonist is ≥0.1 ng / ml; The concentration of the fusion protein agonist is ≥1 ng / ml; The concentration of the fusion protein agonist is ≥10 ng / ml; The concentration of the fusion protein agonist is ≥100 ng / ml.

[0023] In a second aspect, the present invention provides a biomaterial selected from any of the following: E1) Contains a nucleic acid molecule encoding the fusion protein; E2) An expression cassette containing the nucleic acid molecules described in E1); E3) A recombinant vector containing the nucleic acid molecule described in E1), or a recombinant vector containing the expression cassette described in E2); E4) Recombinant microorganisms containing the nucleic acid molecules described in E1), or recombinant microorganisms containing the expression cassette described in E2), or recombinant microorganisms containing the recombinant vector described in E3); E5) Recombinant cells containing the nucleic acid molecule described in E1), or recombinant cells containing the expression cassette described in E2), or recombinant cells containing the recombinant vector described in E3).

[0024] Furthermore, the nucleotide sequence of the nucleic acid molecule described in E1) is as shown in SEQ ID NO: 8 or 13 or has 90% homology with the nucleotide sequence shown in SEQ ID NO: 8 or 13.

[0025] It should be understood that the nucleotide sequence SEQ ID NO. 8 or 13 is a sequence optimized for codon preference of CHO cells; those skilled in the art can optimize the nucleic acid encoding any of the fusion proteins shown in SEQ ID NO: 2-7 according to different expression systems (such as other engineered bacteria), and such variants are all within the scope of protection of this application.

[0026] Further, the recombinant vector described in E3) includes at least one of the following: pcDNA3.4 vector, pOptiVEC vector, pTT5 vector, pCEP4 vector, GS vector, pET series vector, pBAD vector, pGEX series vector, pCAl-n / pCAl-pelB vector, pPOW3.0 vector, pPIC series vector, and pYES2 vector.

[0027] Furthermore, the recombinant microorganisms described in E4) or the recombinant cells described in E5) include at least one of hamster ovary cells, silkworm ovary cells, Pichia pastoris, Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis.

[0028] In one specific embodiment of the present invention, the recombinant cells are eukaryotic cells, preferably mammalian cells, and more preferably CHO cells.

[0029] It should be noted that the present invention does not limit the recombinant microorganisms or recombinant cells mentioned above. Any cell that can express exogenous genes through recombinant engineering technology is protected by the present invention.

[0030] In a third aspect, the present invention provides a pharmaceutical composition comprising the fusion protein and a pharmaceutically acceptable carrier.

[0031] Furthermore, the pharmaceutically acceptable carrier includes at least one of buffer systems, stabilizers and protectants, surfactants, antioxidants, and chelating agents.

[0032] Optionally, the buffer system is a reagent that stabilizes the pH of the solution within a specific range to maintain the conformational and chemical stability of the antibody, including at least one of histidine, citrate / citrate, succinate / succinate, phosphate, acetic acid / acetate, glutamic acid, adipic acid, aspartic acid, lactic acid, tromethamine, and 2-(N-morpholine)-ethanesulfonic acid (MES).

[0033] Optionally, the stabilizer and protectant can be used as a lyophilization protectant (replacing water molecules during lyophilization to protect the protein structure), an isotonic regulator (making the solution isotonic with blood, reducing injection pain), and a viscosity regulator (reducing the viscosity of high-concentration antibodies for easier subcutaneous injection), including at least one of sugars, polyols, amino acids, and salts; wherein the sugars can be sucrose or trehalose (the most commonly used lyophilization protectants and stabilizers); the polyols can be mannitol, sorbitol, or glycerol; the amino acids can be arginine (effectively reducing viscosity and inhibiting aggregation), proline, glycine, or lysine; and the salts can be sodium chloride (NaCl).

[0034] Optionally, the surfactant is a reagent that prevents the antibody protein from agglomerating and degrading under the induction of shock during liquid-gas interface, container surface or transportation, including at least one of polysorbate 20 (PS-20, Tween 20), polysorbate 80 (PS-80, Tween 80), and poloxamer 188.

[0035] In a fourth aspect, the present invention provides the use of the fusion protein, the biomaterial, or the pharmaceutical composition described herein in the preparation of a medicament for treating thrombocytopenia. The application further refers to the use of the fusion protein as a long-acting platelet-boosting drug in clinical treatment, wherein fusion proteins containing M252Y, S254T, and T256E mutations are particularly suitable for treatment regimens with dosing intervals of more than two weeks.

[0036] In a fifth aspect, the present invention provides a method for preparing the fusion protein, the method comprising the following steps: Step 1: Construct recombinant cells or recombinant microorganisms capable of expressing the fusion protein; Step 2: Cultivate the recombinant cells or recombinant microorganisms to obtain the fusion protein.

[0037] Optionally, when constructing recombinant cells, the fusion protein may further include a signal peptide.

[0038] In one specific embodiment of the present invention, the method includes the following steps: The gene sequence encoding the target fusion protein was synthesized, digested with restriction endonucleases, and then ligated into a mammalian expression vector. The recombinant expression vector was transfected into CHO cells and cultured for expression under suitable conditions; The culture supernatant was collected and purified by Protein A affinity chromatography and molecular sieve chromatography to obtain a high-purity fusion protein.

[0039] The beneficial effects of the present invention include, but are not limited to: Break through production process bottlenecks to achieve high-quality, high-volume production: In existing technologies, peptide drugs, such as roprostine, mostly employ prokaryotic expression systems (e.g., E. coli). These systems suffer from inherent drawbacks, including the easy formation of inclusion bodies, incorrect folding conformation, disulfide bond mismatches, and complex purification and refolding processes, severely limiting the efficiency and product quality of large-scale production. This invention innovatively employs a eukaryotic expression system (preferably CHO cells) to express the fusion protein. Eukaryotic systems possess well-developed protein folding and post-translational modification mechanisms, enabling the direct secretion of conformally correct, highly homogeneous, and soluble proteins. This not only completely circumvents the process bottlenecks of prokaryotic expression systems but also significantly improves the yield and purity of the target protein, reduces production complexity and cost, and has promising prospects for industrial application.

[0040] Actively eliminate immunogenicity risks and achieve molecular-level safety optimization: Loprostine, as a prokaryotic expression product, suffers from low immunogenicity due to the passive result of purification processes such as endotoxin removal, and its Fc region still retains some effector functions, posing potential safety risks. This invention addresses this issue by actively introducing specific combinations of mutations from the molecular design stage, achieving systematic optimization of safety. Specifically, by introducing the L234S, L235T, and G236R triple mutations and the L234A and L235A mutations in the Fc region, Fc effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) are completely silenced. Simultaneously, the N297G deglycosylation mutation is introduced to completely eliminate the N-glycosylation site in the Fc region, avoiding the resulting immunogenicity risks and glycosylation heterogeneity. This proactive design strategy ensures that the fusion protein functions as a simple "long-acting agonist" in vivo, fundamentally reducing the incidence of immune-related adverse reactions and significantly improving the long-term safety of the product.

[0041] Develop a complete technology roadmap to provide diverse clinical options: Based on the aforementioned innovative concepts, this invention provides four specific implementation schemes, from basic improvements to final optimization, forming a complete technical route covering different performance requirements. These schemes, while ensuring safety and extending half-life as core advantages, offer differentiated product choices for different clinical scenarios (such as different patient groups and different dosing preferences), greatly enriching the technical pathways and clinical application flexibility, and possessing significant commercial transformation value and broad clinical application prospects. Attached Figure Description

[0042] The accompanying drawings, which are included to provide a further understanding of the invention and form part of this invention, illustrate exemplary embodiments of the invention and are used to explain the invention, but do not constitute an undue limitation of the invention. In the drawings: Figure 1 This is a schematic diagram of the molecular structure of the fusion protein of the present invention. Wherein, Figure 1 A is a schematic diagram of the structure of the fusion protein of wild-type IgG1; Figure 1 Figure B is a schematic diagram of the structure of fusion protein 1 (N297G mutation); Figure 1 The diagram in C represents the structure of fusion protein 2 (L234S / L235T / G236R mutation); Figure 1 D is a schematic diagram of the structure of fusion protein 3 (N297G / L234S / L235T / G236R mutation); Figure 1 E is a schematic diagram of the structure of fusion protein 4 (N297G / L234S / L235T / G236R / M252Y / S254T / T256E mutation); Figure 1 The diagram in Figure F shows the structure of fusion protein 5 (N297G / M252Y / S254T / T256E mutation); Figure 1The diagram shows the structure of fusion protein 6 (N297G / M252Y / S254T / T256E / L234A / L235A mutations). In the diagram, the purple area represents the TPO mimic peptide fragment, the blue area represents the Fc variant fragment, the red asterisk indicates the N297G mutation site, the green triangle indicates the L234S / L235T / G236R mutation sites, the yellow circle indicates the M252Y / S254T / T256E mutation sites, and the purple asterisk indicates the L234A / L235A mutation sites.

[0043] Figure 2 The image shows the SDS-PAGE electrophoresis results of the purified fusion protein. Figure 2 In the figure, A, F represent the electrophoresis results of purified fusion proteins 1-6, and M represents the protein molecular weight standard (unit: kDa). In each figure, lane 1 is the electrophoresis result under reducing conditions, and lane 2 is the electrophoresis result under non-reducing conditions.

[0044] Figure 3 The image shows the SEC-HPLC results of the purified fusion protein. Among them, Figure 3 The figures in the middle (AF) are SEC-HPLC results of purified fusion proteins 1-6, respectively.

[0045] Figure 4 The figures show the binding and dissociation curves of the fusion protein and FcγRI. Among them, Figure 4 The middle and lower bounds (AD) represent fusion protein 1, fusion protein 5, fusion protein 6, and the wild-type IgG1 fusion protein control, respectively.

[0046] Figure 5 The figures show the binding and dissociation curves of the fusion protein with FcγRIIa-R167. Figure 5 The middle and lower A and D values ​​represent fusion 1, fusion protein 5, fusion protein 6, and IgG1 wild-type fusion protein controls, respectively.

[0047] Figure 6 The figures show the binding and dissociation curves of the fusion protein with FcγRIIa-H167. Figure 6 The middle and lower A and D values ​​represent fusion 1, fusion protein 5, fusion protein 6, and IgG1 wild-type fusion protein controls, respectively.

[0048] Figure 7 The figures show the binding and dissociation curves of the fusion protein with FcγRⅢa-V176. Figure 7 The middle and lower bounds (AD) represent fusion protein 1, fusion protein 5, fusion protein 6, and the wild-type IgG1 fusion protein control, respectively.

[0049] Figure 8 The figures show the binding and dissociation curves of the fusion protein with FcγRⅢa-F176. Figure 8The middle and lower bounds (AD) represent fusion protein 1, fusion protein 5, fusion protein 6, and the wild-type IgG1 fusion protein control, respectively.

[0050] Figure 9 This is a diagram showing the binding of fusion protein molecule 1 to FcRn. Among them, Figure 9 In the figure, A is the fitted curve. Figure 9 Figure B in the middle represents the original data.

[0051] Figure 10 This is a diagram showing the binding of fusion protein molecule 5 to FcRn. Among them, Figure 10 Original data chart of China A Figure 10 Plot B shows the residual response data.

[0052] Figure 11 This is a diagram showing the binding of fusion protein molecule 6 to FcRn. Among them, Figure 11 In the middle, A represents the original data. Figure 11 Plot B shows the residual response data.

[0053] Figure 12 This is a graph showing the binding of wild-type IgG1 fusion protein molecules to FcRn. Among them, Figure 12 In the figure, A is the fitted curve. Figure 12 Figure B in the middle represents the original data.

[0054] Figure 13 The results of in vitro TPO receptor agonist activity assays for the fusion proteins show the activation capacity of each fusion protein on TPO reporter cells at different concentrations. Among them, Figure 13 A represents the results of fusion protein molecules 1-3; among them, Figure 13 B represents the results of fusion protein molecules 4-6 in the figure. The fusion protein molecules in the figure are abbreviated as protein. Detailed Implementation

[0055] The present invention is described in detail below with reference to the embodiments, but the present invention is not limited to these embodiments. Unless otherwise specified, the raw materials and catalysts in the embodiments of the present invention are all purchased through commercial channels.

[0056] definition: The EU index is a numbering system based on the amino acid sequence of human IgG1 myeloma protein (EU). Because different antibody subtypes vary in length, direct sequential numbering leads to alignment difficulties. Therefore, the EU protein is used as a "standard ruler" to uniformly label the key functional sites of all IgG antibodies. It is important to note that the numbers in the EU index (such as L234) are not equivalent to the physical sequence number of the amino acids; they are a fixed coordinate system adjusted for alignment.

[0057] Fc variant fragments: These are engineered fragments obtained by substituting, inserting, or deleting amino acids from human IgG Fc fragments.

[0058] Eukaryotic expression system: refers to a system that uses eukaryotic host cells such as mammalian cells and yeast cells to express proteins.

[0059] Example 1: Molecular design and gene synthesis of fusion proteins Based on the natural sequence of human IgG1 Fc (refer to UniProt database number P01857), six fusion protein structures were designed. All fusion proteins adopted the same structural framework as roprostine: human IgG1 Fc variant fragment - (G)5 linker peptide - double tandem TPO mimic peptide fragment. The TPO mimic peptide adopted a known sequence with high agonistic activity (amino acid sequence as shown in SEQ ID NO: 1).

[0060] The specific mutation design is as follows (refer to the EU index numbering system): Fusion protein 1: An N297G single-point mutation was introduced into the Fc variant fragment (amino acid sequence as shown in SEQ ID NO: 2).

[0061] Fusion protein 2: The L234S, L235T and G236R three-point mutations (abbreviated as LLG→STR mutation) are introduced into the Fc variant fragment (amino acid sequence as shown in SEQ ID NO: 3).

[0062] Fusion protein 3: Contains both N297G mutation and L234S, L235T, and G236R mutations (amino acid sequence as shown in SEQ ID NO: 4).

[0063] Fusion protein 4: Based on fusion protein 3, further M252Y, S254T and T256E mutations (referred to as YTE mutation) are introduced (amino acid sequence as shown in SEQ ID NO: 5).

[0064] Fusion protein 5: Based on fusion protein 1, further M252Y, S254T and T256E mutations are introduced (amino acid sequences are shown in SEQ ID NO: 6).

[0065] Fusion protein 6: Based on fusion protein 5, further L234A and L235A mutations are introduced (amino acid sequence as shown in SEQ ID NO: 7). A schematic diagram of the fusion protein molecular structure is shown below. Figure 1 As shown.

[0066] The gene sequences were optimized based on the codon bias of mammalian cells, and a professional biotechnology company was commissioned to synthesize the complete gene sequences encoding the above six fusion proteins. The synthesized gene sequences are shown in SEQ ID NO: 8-13, respectively.

[0067] The nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 2 are shown in SEQ ID NO: 8; the nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 3 are shown in SEQ ID NO: 9; the nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 4 are shown in SEQ ID NO: 10; the nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 5 are shown in SEQ ID NO: 11; the nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 6 are shown in SEQ ID NO: 12; and the nucleotide sequences of the nucleic acid molecules encoding the amino acid sequence shown in SEQ ID NO: 7 are shown in SEQ ID NO: 13.

[0068] Example 2: Construction of expression vector and cell transfection The synthesized gene fragment was digested with restriction endonucleases NotI and XbaI, and then ligated into the mammalian expression vector pcDNA3.4, which had been digested with the same enzymes. The ligation products were transformed into E. coli DH5α competent cells, and positive clones were selected by ampicillin resistance screening. The correct clones were verified by colony PCR and sequencing and used for subsequent experiments.

[0069] Obtain ExpiCHO-S cells (Thermo Fisher Scientific) in logarithmic growth phase and adjust the density to 3 × 10⁻⁶. 6 cells / mL. Take 30 μg of each of the four recombinant plasmids mentioned above and transfect them using ExpiFectamine CHO transfection reagent according to the manufacturer's recommended protocol. After transfection, cells are cultured at 37 °C and 8% CO2. ExpiCHO Enhancer is added on day 1 post-transfection, and culture continues until day 14.

[0070] Example 3: Protein Expression and Purification After culture, the cell culture supernatant was collected and filtered through a 0.22 μm filter membrane. Purification was performed using the AKTA pure protein purification system. Step 1: Protein A affinity chromatography: The filtered supernatant was loaded onto a pre-equilibrated MabSelectSuRe column (Cytiva) at a flow rate of 5 mL / min. After loading, the sample was washed with 20 mM sodium phosphate, 150 mM NaCl, and pH 7.4 buffer until baseline stability was achieved. The target protein was eluted with 0.1 M glycine-hydrochloric acid buffer (pH 3.0) and immediately neutralized to pH 7.0 with 1 M Tris-HCl (pH 8.0). Step 2: Molecular sieve chromatography: The sample collected from affinity chromatography was concentrated to an appropriate volume and loaded onto a HiLoad 16 / 600 Superdex 200 pg column (Cytiva). Separation was performed with PBS buffer (pH 7.4) at a flow rate of 1 mL / min. The eluted fraction corresponding to the main peak was collected, which was the purified fusion protein. Following the purification process described above, the expression yields of fusion proteins 1-6 were 0.56 g / L, 0.79 g / L, 0.61 g / L, 0.69 g / L, 0.775 g / L, and 0.924 g / L, respectively. SDS-PAGE analysis of both reduced and non-reduced proteins (…) Figure 2 All samples showed a single band, with apparent molecular weights of approximately 29 kDa for the monomer and 58 kDa for the dimer, consistent with theoretical predictions. Furthermore, SEC-HPLC results indicated that the monomer purity was above 95%. Figure 3 ).

[0071] Example 4: Biofilm layer interferometry (BLI) was used with OctetR4 to determine the binding affinity of fusion proteins 1, 5, 6, and the IgG1 control (trastuzumab biosimilar, Gembay) to human FcγⅠ, FcγⅡa, and FcγⅢa. Spray spectroscopy (SPR) was used with a Biacroe T200 instrument to determine the binding affinity of fusion proteins 1, 5, 6, and the IgG1 control to FcRn. The corresponding receptor proteins were immobilized using an SA biosensor or a CM5-anti-his chip, and the target proteins were captured. The dilution buffer was HBS. P buffer and glycine solution were used as regeneration buffer. Baseline stabilization, protein loading, binding, and dissociation steps were performed sequentially, and kinetic signals were acquired. During the data analysis phase, blank sensor reference subtraction and Y-axis alignment were performed to obtain the binding sensor map (see Figure 4-12). The data were fitted using either dynamic kinetic fitting or static equilibrium fitting methods, and the affinity constant was calculated. Specific affinity constant data are shown in the table below.

[0072] Table 1. Affinity constants (KD) of proteins 1, 5, and 6 with the Fc receptor

[0073] IgG1 control (Trastuzumab, WT) Fc) for each FcγR receptor subtype (FcγRI, FcγRIIa-R167, FcγRIIa-H167, FcγRIIIa) Both V176 and FcγR receptors showed significant binding signals, with the sensing curves rising rapidly and exhibiting typical binding kinetics, confirming that wild-type IgG1 Fc has affinity for the aforementioned FcγR receptor.

[0074] Fusion proteins 1, 5, and 6 are related to the tested receptors except FcγRIIIa. Kinetic parameters could be fitted to all F176, and a detectable specific binding response was observed. However, the overall KD value was significantly higher than that of the IgG1 control (decreased affinity), indicating that the binding activity of all three to the FcγR receptor was weakened to varying degrees.

[0075] Affinity assays of the target proteins with the FcγRI receptor showed that the affinity of fusion protein 1 decreased by 520.3-fold compared to the wild type, the affinity of fusion protein 5 decreased by 291.3-fold, and the affinity of fusion protein 6 decreased by 7804.6-fold. All three showed a significant decrease in binding ability, with fusion protein 6 exhibiting the weakest binding affinity to FcγRI. However, we also observed that the long-acting YTE mutation did not exhibit the decreasing affinity for FcγRI associated with the N297G mutation; in fact, the affinity increased by nearly 100% compared to the N297G mutation. The addition of the L234A-L235A mutation further significantly reduced the affinity for FcγRI. The FcγRI receptor can bind to free monomeric molecules containing the Fc region in serum, such as IgG and the molecule in this case. This can mediate the efficient phagocytosis of Fc-containing IgG1 / IgG3 by macrophages / monocytes, as well as target cells, pathogens, and immune complexes modulated by the molecule in this case—the ADCP effect; it also mediates the ADCC effect derived from macrophages / monocytes. The decreased affinity of the molecule in this case for the FcγRI receptor can effectively reduce ADCC and ADCP effects, decreasing the killing or phagocytic effect on megakaryocytes and platelets expressing the MPL receptor, thereby improving safety.

[0076] Affinity assays of the target protein with the FcγRIIa receptor showed that, compared to wild-type IgG1, the affinity for FcγRIIa was significantly higher. Binding to R167 resulted in a 16.6-fold decrease in affinity for fusion protein 1; a 7.3-fold decrease in affinity for fusion protein 5; and a 6.0-fold decrease in affinity for fusion protein 6, along with FcγRIIa. The binding affinity of fusion protein 1 to H167 decreased by 27.6-fold; that of fusion protein 5 decreased by 12.1-fold; and that of fusion protein 6 decreased by 3.6-fold. Fusion protein 1 showed the weakest affinity for the FcγRIIa receptor. Although the binding affinity of all three constructed proteins to the FcγRIIa receptor was weaker than that of wild-type IgG1, the binding affinity of the target fusion protein 6 (containing N297G and YTE mutations superimposed with LALA mutation) to FcγRIIa showed a different trend compared to that of protein 1 (N297G mutation) or protein 5 (N297G & YTE mutation). These results also indicate that although theoretically the L234A-L235A mutation can reduce the binding affinity of Fc to the FcγR receptor, the binding affinity of the L234A-L235A mutation to the FcγRII receptor in this study did not further decrease compared to fusion proteins 1 and 5. Therefore, theoretical predictions cannot replace the verification of experimental data.

[0077] Affinity assays of the target protein with the FcγRIIIa receptor showed that, compared to wild-type IgG1, the affinity for FcγRIIIa was significantly higher. V176 receptor binding: Fusion protein 1 affinity decreased by 29.2-fold; fusion protein 5 affinity decreased by 8.5-fold; fusion protein 6 affinity decreased by 4.3-fold. Fusion protein 1 binds to FcγRIIIa. The V176 receptor has the lowest affinity. It targets FcγRIIIa. F176 receptor: Wild-type IgG1 can stably bind to this receptor (KD=8.304E). 08); No binding response was detected in fusion proteins 1, 5, and 6, and the designed point mutation combination achieved a complete loss of the receptor binding activity.

[0078] As is well known, the binding of the Fc segment of the antibody / Fc fusion protein to the FcγR family mediates antibody-mediated cytotoxicity (ADCC) and antibody-mediated phagocytosis (ADCP). The protein of the present invention has reduced binding ability to agonistic FcγR family receptors. Based on the above data, it can be inferred that the molecule of the present invention has better safety than the original sequence molecule. That is, after the TPO peptide portion of the molecule of the present invention binds to MPL cells on the surface of megakaryocytes or platelets, the ADCC or ADCP effect has less impact on megakaryocytes and platelets.

[0079] On the other hand, experimental data demonstrate that, compared to wild-type IgG1 control antibodies, fusion protein 1 exhibits a 5.56-fold increase in affinity for the FcRn receptor; fusion protein 5 a 48.3-fold increase; and fusion protein 6 a 48.5-fold increase. Classical antibody theory posits that antibody molecules with high FcRn affinity (Fc fragment) have a longer in vivo half-life. The novel mutant combinations of one or more amino acid sites introduced into fusion proteins 1, 5, and 6 result in all three fusion proteins possessing superior Fc binding ability to the FcRn receptor compared to wild-type IgG1. Therefore, it is reasonable to conclude that these three molecules have a longer in vivo half-life compared to their wild-type counterparts. Consequently, the molecules in this project exhibit a superior in vivo half-life compared to prokaryotically expressed roprostine, allowing for the development of drugs with lower dosing frequencies or better patient compliance.

[0080] Example 5: TPO receptor activity detection The activation function of the fusion protein on the TPO receptor was detected using the M07e cell line, which natively expresses the human TPO receptor. M07e cells in the logarithmic growth phase with viability greater than 90% were resuspended in basal medium and their density adjusted to 2 × 10⁻⁶ cells / year. 5 Cells / mL. The reference product, roprostine, and the six fusion proteins from Example 1 were serially diluted with basal medium to prepare nine concentration points (200 ng / mL to 0.004 ng / mL) for testing. In a 96-well plate, 50 μL of the diluted sample solution was added to each well, with three replicates for each concentration. A negative control group was also included, with only basal medium added. Subsequently, 50 μL of cell suspension was added to each well, and the plates were incubated at 37°C and 5% CO2 for 72 hours. After incubation, 10 μL of CCK-8 solution was added to each well, and the plates were incubated for another 2 hours. The absorbance at 450 nm and 600 nm was measured using a microplate reader. The cell proliferation rate at each concentration was calculated, and dose-response curves for the test sample and the reference product were plotted. The proliferation rate was calculated using the following formula: Proliferation rate

[0081] like Figure 13 As shown, all test substances promoted cell proliferation in a dose-dependent manner. For clarity, test substance fusion proteins 1-3 and test substance fusion proteins 4-6 are shown in [the diagram / illustration]. Figure 13 Figures A and B are shown, with the positive control roprostine also displayed in both figures. Theoretically, since the active ingredients and peptide-like moieties of each molecule are the same as roprostine, the in vitro activity of each candidate protein should be comparable to that of roprostine. However, the experimental results show that this is not consistent with theoretical predictions. From... Figure 13It can be seen that the activities of fusion protein 2 and fusion protein 1 are superior to the positive control drug roprostine across the entire concentration range. However, the cell proliferation-promoting activity of fusion protein 3, constructed by superimposing the designed mutation sites in fusion protein 1 and fusion protein 2, was not further enhanced. The activity of fusion protein 3 was lower than that of fusion protein 1 and fusion protein 2 at all tested concentrations, and even slightly lower than that of the control drug in the concentration range of 0.02-100 ng / mL. The relative proliferation rate of fusion protein 2 exceeded 6-fold at a concentration of 200 ng / mL. The activities of fusion proteins 4, 5, and 6 were also generally superior to roprostine. However, we noted that the cell proliferation-promoting effects of fusion proteins 4 and 5 were reversed at a high concentration of 200 ng / mL, especially fusion protein 4, which almost completely lost its cell proliferation-promoting effect at a high concentration of 200 ng / mL. In contrast, fusion protein 6, which also had multiple mutations, showed a better cell proliferation-promoting effect.

[0082] The above description is merely an embodiment of the present invention, and the scope of protection of the present invention is not limited to these specific embodiments, but is determined by the claims of the present invention. For those skilled in the art, the present invention can have various modifications and variations. Any modifications, equivalent substitutions, improvements, etc., made within the technical concept and principle of the present invention should be included within the scope of protection of the present invention.

Claims

1. A long-acting platelet-boosting drug fusion protein, characterized in that, The fusion protein comprises an Fc variant fragment of human immunoglobulin G (IgG) and a thrombopoietin receptor-binding peptide fragment, wherein: The Fc variant fragment includes one or more amino acid substitutions selected from the group consisting of the amino acid sequence shown in SEQ ID NO: 14: A1) Replace L234A and L235A located at positions 234 and 235 of the EU index; A2) Replaced by N297G located at position 297 of the EU index; A3) Replaces M252Y, S254T, and T256E located at positions 252, 254, and 256 of the EU index.

2. The fusion protein according to claim 1, wherein the thrombopoietin receptor-binding peptide fragment comprises the amino acid sequence shown in SEQ ID NO:

1.

3. The fusion protein according to claim 1 or 2, characterized in that, The Fc variant fragment includes an amino acid substitution selected from any of the following in the amino acid sequence shown in SEQ ID NO: 14: B1) Replaced by N297G located at position 297 of the EU index; B2) Replace L234A and L235A located at positions 234 and 235 of the EU index; and N297G, located at position 297 of the EU index, is replaced; and M252Y, S254T, and T256E, located at positions 252, 254, and 256 of the EU index, are replaced.

4. The fusion protein according to claim 1, characterized in that, The amino acid sequence of the fusion protein includes at least one of the following: C1) The amino acid sequence as shown in SEQ ID NO: 2 or 7; C2) A fusion protein with the same function is obtained by attaching a tag protein to the N-terminus and / or C-terminus of the fusion protein described in A1).

5. A biomaterial, characterized in that, The biomaterial is selected from any one of the following: D1) Contains a nucleic acid molecule encoding any of the fusion proteins described in claims 1-4; D2) An expression cassette containing the nucleic acid molecules described in D1); D3) A recombinant vector containing the nucleic acid molecule described in D1), or a recombinant vector containing the expression cassette described in D2); D4) Recombinant microorganisms containing the nucleic acid molecules described in D1), or recombinant microorganisms containing the expression cassette described in D2), or recombinant microorganisms containing the recombinant vector described in D3); D5) Recombinant cells containing the nucleic acid molecules described in D1), or recombinant cells containing the expression cassette described in D2), or recombinant cells containing the recombinant vector described in D3).

6. The biomaterial according to claim 5, characterized in that, The nucleotide sequence of the nucleic acid molecule described in D1) is shown in SEQ ID NO: 8 or 13.

7. The biomaterial according to claim 5, characterized in that, The recombinant microorganisms described in D4) or the recombinant cells described in D5) include at least one of hamster ovary cells, silkworm ovary cells, Pichia pastoris, Saccharomyces cerevisiae, Escherichia coli, and Bacillus subtilis.

8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises the fusion protein of any one of claims 1-4, a pharmaceutically acceptable drug, and an excipient.

9. Use of the fusion protein of any one of claims 1-4, the biomaterial of any one of claims 5-7, or the pharmaceutical composition of claim 8 in the preparation of a medicament for treating thrombocytopenia.

10. A method for preparing the fusion protein described in any one of 1-4, characterized in that, The method includes the following steps: Step 1: Construct recombinant cells or recombinant microorganisms capable of expressing any of the fusion proteins described in claims 1-4; Step 2: Cultivate the recombinant cells or recombinant microorganisms to obtain the fusion protein.